Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), American Well (AMWL) and BridgeBio Pharma (BBIO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx Pharmaceutical (RARE – Research Report), American Well (AMWL – Research Report) and BridgeBio Pharma (BBIO – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ultragenyx Pharmaceutical (RARE)
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Ultragenyx Pharmaceutical yesterday. The company’s shares closed last Thursday at $23.50.
According to TipRanks.com, Rama is a 5-star analyst with an average return of
Ultragenyx Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $57.71, a 140.9% upside from current levels. In a report issued on January 30, Morgan Stanley also maintained a Buy rating on the stock with a $50.00 price target.
See today’s best-performing stocks on TipRanks >>
American Well (AMWL)
In a report released today, Ryan MacDonald from Needham reiterated a Hold rating on American Well. The company’s shares closed last Thursday at $4.33.
According to TipRanks.com, MacDonald has 0 stars on 0-5 stars ranking scale with an average return of
American Well has an analyst consensus of Hold, with a price target consensus of $5.33, representing a 22.0% upside. In a report released yesterday, BTIG also maintained a Hold rating on the stock.
BridgeBio Pharma (BBIO)
In a report released yesterday, William Pickering from Bernstein assigned a Buy rating to BridgeBio Pharma, with a price target of $94.00. The company’s shares closed last Thursday at $76.06.
According to TipRanks.com, Pickering is a 3-star analyst with an average return of
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $100.69, implying a 18.7% upside from current levels. In a report issued on January 29, TD Cowen also maintained a Buy rating on the stock with a $95.00 price target.
